PL377857A1 - Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluorometylo-fenylo)-etylo]-metyloamidu kwasu 4-(S)-(4-acetylo-piperazyn-1-ylo)-2-(R)-(4-fluoro-2-metylo-fenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków - Google Patents

Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluorometylo-fenylo)-etylo]-metyloamidu kwasu 4-(S)-(4-acetylo-piperazyn-1-ylo)-2-(R)-(4-fluoro-2-metylo-fenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków

Info

Publication number
PL377857A1
PL377857A1 PL377857A PL37785704A PL377857A1 PL 377857 A1 PL377857 A1 PL 377857A1 PL 377857 A PL377857 A PL 377857A PL 37785704 A PL37785704 A PL 37785704A PL 377857 A1 PL377857 A1 PL 377857A1
Authority
PL
Poland
Prior art keywords
phenyl
methylamide
paroxetine
piperazin
anxiety
Prior art date
Application number
PL377857A
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Renzo Carletti
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL377857A1 publication Critical patent/PL377857A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL377857A 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluorometylo-fenylo)-etylo]-metyloamidu kwasu 4-(S)-(4-acetylo-piperazyn-1-ylo)-2-(R)-(4-fluoro-2-metylo-fenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków PL377857A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments

Publications (1)

Publication Number Publication Date
PL377857A1 true PL377857A1 (pl) 2006-02-20

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
PL377858A PL377858A1 (pl) 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków
PL377857A PL377857A1 (pl) 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluorometylo-fenylo)-etylo]-metyloamidu kwasu 4-(S)-(4-acetylo-piperazyn-1-ylo)-2-(R)-(4-fluoro-2-metylo-fenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL377858A PL377858A1 (pl) 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków

Country Status (18)

Country Link
US (4) US20060241143A1 (pl)
EP (4) EP1653956A1 (pl)
JP (4) JP2006523651A (pl)
KR (2) KR20060003876A (pl)
CN (2) CN1809355A (pl)
AU (2) AU2004229181A1 (pl)
BR (2) BRPI0409377A (pl)
CA (2) CA2522311A1 (pl)
CO (1) CO5700753A2 (pl)
GB (1) GB0308968D0 (pl)
IS (2) IS8128A (pl)
MA (2) MA27731A1 (pl)
MX (2) MXPA05011064A (pl)
NO (2) NO20055367L (pl)
PL (2) PL377858A1 (pl)
RU (2) RU2005135647A (pl)
WO (4) WO2004091616A1 (pl)
ZA (2) ZA200508067B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en) * 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
JP2003522739A (ja) * 1999-12-17 2003-07-29 シェーリング コーポレイション 選択的ニューロキニンアンタゴニスト
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
EP1451153B1 (en) * 2001-11-13 2007-09-26 Schering Corporation Nk1 antagonists
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
GB0308968D0 (en) 2003-05-28
EP1615642A1 (en) 2006-01-18
CN1809359A (zh) 2006-07-26
JP2006523652A (ja) 2006-10-19
WO2004091617A1 (en) 2004-10-28
IS8128A (is) 2005-11-15
US20060241124A1 (en) 2006-10-26
CA2522313A1 (en) 2004-10-28
CA2522311A1 (en) 2004-10-28
MXPA05011064A (es) 2006-04-18
MA27731A1 (fr) 2006-01-02
EP1613325A1 (en) 2006-01-11
NO20055367L (no) 2005-11-14
US20060217395A1 (en) 2006-09-28
AU2004229181A1 (en) 2004-10-28
IS8129A (is) 2005-11-15
US20060241143A1 (en) 2006-10-26
WO2004091624A1 (en) 2004-10-28
JP2006523649A (ja) 2006-10-19
US20060287325A1 (en) 2006-12-21
EP1615641A1 (en) 2006-01-18
WO2004091616A1 (en) 2004-10-28
ZA200508067B (en) 2007-02-28
JP2006523651A (ja) 2006-10-19
CO5700753A2 (es) 2006-11-30
MA27730A1 (fr) 2006-01-02
BRPI0409379A (pt) 2006-04-25
BRPI0409377A (pt) 2006-04-25
EP1653956A1 (en) 2006-05-10
ZA200508068B (en) 2007-02-28
CN1809355A (zh) 2006-07-26
JP2006523650A (ja) 2006-10-19
KR20060003876A (ko) 2006-01-11
WO2004091615A1 (en) 2004-10-28
AU2004229179A1 (en) 2004-10-28
MXPA05011063A (es) 2005-12-12
RU2005135647A (ru) 2006-06-10
KR20060003875A (ko) 2006-01-11
NO20055368L (no) 2005-11-14
PL377858A1 (pl) 2006-02-20
RU2005135649A (ru) 2006-03-20

Similar Documents

Publication Publication Date Title
EP1620095A4 (en) HEMMER OF ACT ACTIVITY
SI1499589T1 (sl) Derivati N-(fenil(piperidin-2-il)metil)benzamida,njihova priprava in njihova terapevtska uporaba
EP1784175A4 (en) INHIBITORS OF ACT ACTIVITY
EP1737861A4 (en) HEMMER OF ACT ACTIVITY
EP1496906A4 (en) HEMMER OF ACT ACTIVITY
IL196847A0 (en) P38 inhibitors and method of use thereof
ZA200700481B (en) N-(1-(1-beznyl-4-pheynl-1H-imidazol-2-yl)-2,2-dymenthylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
EP1814484A4 (en) ATRIAL ABLATION CATHETER AND METHOD FOR ITS USE
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
EP1556057A4 (en) MEDIUM AND METHOD FOR REINFORCING BONE TRAINING
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2003303287A8 (en) Method of cardiac risk assessment
IL174127A0 (en) Apparatus for, and method of, determining the condition of a patient's heart
AU2003262033A8 (en) Method for managing use of storage region by application
PL373946A1 (pl) Fenoksy-piperydyny do leczenia chorób takich jak schizofrenia i depresja
IL164645A (en) Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1h- benzidimazole-2-yl]-1- piperidinyl] ethyl]- alpha, alpha- dimethyl - benzenoacetic acid, method of preparing the same and use of the same in the preparation of medicaments
AU2003287354A1 (en) An intracardiac catheter and method of use
PL377858A1 (pl) Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
AU2003277215A8 (en) Novel neurokinin antagonists and methods of use thereof
FI20031628A0 (fi) Tietokoneryväs, tietokoneyksikkö ja menetelmä muistisaannin ohjaukseen tietokoneyksiköiden välillä
PL366690A1 (pl) Nowe pochodne 4,5,6,7-tetrabromobenzimidazolu oraz sposób ich otrzymywania
HK1089948A (en) Combinations of paroxetine and 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid -1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]methylamide for treatment of depression and/or anxiety
HK1090540A (en) Combinations comprising paroxetine and 2-(s)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(r)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or anxiety
AU2003299507A8 (en) Hop - a novel cardiac-restricted transcriptional factor potentially useful for cardiac regeneration and specification

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)